Browsing by Author "Wayengera, Misaki"
-
The contribution of medical biotechnology in the sustainability of human society
Byarugaba, Wilson; Wayengera, Misaki (2010) -
In silico evidence for the species-specific conservation of mosquito retroposons: implications as a molecular biomarker
Byarugaba, Wilson; Kajumbula, Henry; Wayengera, Misaki (BioMed Central, 2009)Background: Mosquitoes are the transmissive vectors for several infectious pathogens that affect man. However, the control of mosquitoes through insecticide and pesticide spraying has proved difficult in the past. We ... -
Searching for new clues about the molecular cause of endomyocardial fibrosis by way of in SilicoProteomics and analytical chemistry
Wayengera, Misaki (Public Library of Science, 2009-10-12)Background: Endomyocardial Fibrosis (EMF) –is a chronic inflammatory disease of the heart with related pathology to that of late stage Chaga’s disease. Indeed, both diseases are thought to result from auto-immune responses ... -
Smart, nano-engineered drug (NRTI)-immune conjugates for targeting HIV within reservoirs
Wayengera, Misaki (BioMed Central, 2011-07-22)Background: Infection with HIV, which culminates in the establishment of a latent proviral reservoir, presents formidable challenges for ultimate cure. Building on the hypothesis that ex-vivo or even in-vivo abolition or ... -
Targeting persistent HIV infection: where and how, if possible?
Wayengera, Misaki (Elsevier, 2011)Sanctuaries of persistent human immunodeficiency virus (HIV) infection, which are diverse and stillincompletely resolved, account for the incomplete clearance of HIV among infected persons with a long-standing history of ... -
Theoretical basis for reducing time-lines to the determination of positive Mycobacterium tuberculosis cultures using thymidylate kinase (TMK) assays
Wayengera, Misaki (BioMed Central, 2009-03-18)Background: In vitro culture of pathogens on growth media forms a "pillar" for both infectious disease diagnosis and drug sensitivity profiling. Conventional cultures of Mycobacterium tuberculosis (M.tb) on Lowenstein ... -
Why bacteria derived R-M nucleic enzymatic peptides are likely efficient therapeutic molecules for use in the design and development of novel HIV inhibitory strategies
Wayengera, Misaki (Academic Journals, 2008-06-17)In the past, we have identified, described and isolated over 200 bacteria derived Restriction Modification (R-M) nucleic enzymatic peptides as efficient therapeutic molecules for use in the development of novel HIV inhibitory ...